Bonus Material-36_High Yield Top 10, 8.25

Pdf Summary

This high-yield summary from the CHEST Pulmonary Board Review (August 2025) by Dr. Saadia Faiz covers critical updates in COPD, bronchiectasis, non-tuberculous mycobacteria (NTM), tuberculosis, lung cancer, respiratory physiology, and thoracic radiology.<br /><br />For COPD, new pharmacological treatments include Ensifentrine (PDE3&4 inhibitor, ENHANCE trial 2024), Roflumilast (PDE4 inhibitor, REACT trial 2015), and biologics such as Dupilumab (BOREAS and NOTUS NEJM 2023) and Mepolizumab (MATINEE NEJM 2025). Initial treatment adds inhaled corticosteroids (ICS) for symptomatic patients on LAMA/LABA, particularly with elevated blood eosinophils or frequent exacerbations.<br /><br />Bronchiectasis etiology is broad: post-infectious airway injury (pneumonia, TB), tumors, congenital disorders (e.g., cystic fibrosis confirmed by sweat chloride and CFTR mutation, primary ciliary dyskinesia with nitric oxide and ciliary testing, alpha-1 antitrypsin deficiency), immunodeficiencies (CVID, HIV, hematologic malignancy), autoimmune conditions, aspiration, and others. Management includes mucociliary clearance, antibiotics (oral/nebulized), bronchodilators, rehabilitation, and emerging treatments like the DPP1 inhibitor brensocatib (ASPEN trial 2025), which reduces exacerbations and improves FEV1.<br /><br />Lung cancer staging follows the 9th edition TNM classification with detailed M categories reflecting sites and extent of metastasis. Management of drug-induced pneumonitis from immune checkpoint inhibitors, targeted therapies, or antibody-drug conjugates involves identifying toxicity grade, drug discontinuation, and corticosteroids, with no drug rechallenge.<br /><br />Pulmonary function testing (PFT) now emphasizes physiological classification rather than clinical diagnosis. Bronchodilator response is defined as a 10% predicted increase in FEV1 or FVC. Z-score ranges classify severity: mild (-1.65 to -2.5), moderate (-2.51 to -4), severe (<-4.1).<br /><br />These updates integrate recent key trials and guidelines, equipping pulmonary clinicians for board exams and clinical practice improvements.

Meta Tag

Concept Chronic Obstructive Pulmonary Disease

Concept Bronchiectasis

Concept M1 Subcategory

Concept Drug-Related Pneumonitis

Concept Muscarinic Antagonist

Keywords

COPD

Chronic Obstructive Pulmonary Disease

bronchiectasis

NTM

tuberculosis

lung cancer

pulmonary function testing

Ensifentrine

Dupilumab

brensocatib

thoracic radiology

Chronic Obstructive Pulmonary Disease

Bronchiectasis

M1 Subcategory

Drug-Related Pneumonitis

Muscarinic Antagonist

COPD